一般演題（口演）24 MET・RET

[O24-4] ABBV-400, a c-Met-Targeting ADC, for Advanced EGFR WT NSQ NSCLC：Results From a Phase 1 Study

Maria De Miguel¹, ^○Noboru Yamamoto², Judith Raimbourg³, Byoung Chul Cho⁴, Maya Gottfried⁵, Salomon M Stemmer⁶, Jonathan Goldman⁷, Martha Blaney⁸, Teddy Jennaro⁸, Athan Vasilopoulos⁸, Rachel Rui Li⁸, Kevin J Freise⁸, Martha Neagu Aristide⁸, Gladys Morrison-Thiele⁸, Zoe N Hunter⁸, Michael Burns⁸, D. Ross Camidge⁹, Takuro Sakagami³ (1.START-Madrid CIOCC HM Sanchinarro, Madrid, Spain, 2.National Cancer Center Hospital, Tokyo, Japan, 3.Institut de Cancerologie de l'Ouest, F-44805 Saint Herblain, France, 4.Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, 5.Meir Medical Center, Tel Aviv University, Tel Aviv, Israel, 6.Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva/Sackler Faculty of Medicine, Petah Tikva, Israel, 7.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 8.AbbVie Inc, North Chicago, IL, USA, 9.University of Colorado Cancer Center, Aurora, CO, USA)

アンコール演題